Proper Name: Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant
Manufacturer: GlaxoSmithKline Biologicals
16 October 2009, Cervarix® was approved for use in the United States, by the FDA. To examine all available FDA documents pertaining to the approval of this HPV vaccine visit the two FDA links below.
Proper Name: Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, RecombinantProduct Information and Supporting Documents
Approval History, Letters, Reviews, and Related Documents – Cervarix®
November 2010, FDA approval for labeling change – Cervarix®